Early detection is crucial in the battle against breast cancer. This systematic review explores the potential of artificial intelligence (AI) in predicting future breast cancer risk using mammograms. We analyze existing studies to evaluate the accuracy, reliability, and clinical implications of AI-driven risk assessment models. By understanding the strengths and limitations of these models, we aim to inform future research and clinical practice.
Breast cancer remains a significant public health concern worldwide. Early detection through regular mammograms has been instrumental in reducing mortality rates. However, mammograms have limitations in predicting future cancer risk. Recent advancements in artificial intelligence (AI) offer promising opportunities to improve breast cancer risk assessment. This review delves into the current state of AI-driven mammography-based breast cancer risk prediction models.
Artificial intelligence has made remarkable strides in various fields, including healthcare. In radiology, AI algorithms have demonstrated exceptional performance in detecting abnormalities in medical images. Specifically, AI-powered mammogram analysis has shown promise in identifying subtle signs of breast cancer that might be missed by human radiologists.
Beyond detecting existing cancers, AI has the potential to predict the likelihood of developing breast cancer in the future. By analyzing mammographic images, AI algorithms can identify subtle patterns and features associated with increased risk. These models could be used to prioritize screening, target preventive interventions, and ultimately reduce breast cancer mortality.
To conduct this review, we systematically searched relevant databases for studies investigating AI-driven mammography-based breast cancer risk prediction. Inclusion and exclusion criteria were defined to ensure the quality and relevance of included studies. The extracted data included study design, sample size, AI algorithm, performance metrics, and clinical implications.
The included studies demonstrated varying levels of accuracy in predicting breast cancer risk using AI-driven mammogram analysis. Several factors influenced model performance, including the type of AI algorithm, dataset size, and image quality. While some studies reported promising results, further research is needed to validate these findings in larger and more diverse populations.
The integration of AI-driven breast cancer risk prediction models into clinical practice could revolutionize preventive care. By identifying women at higher risk, healthcare providers can offer tailored screening and prevention strategies. However, challenges such as model interpretability, ethical considerations, and patient acceptance must be addressed.
AI-driven mammography-based breast cancer risk prediction holds significant promise for improving early detection and prevention. While the field is still in its early stages, the potential benefits are substantial. Continued research and development are essential to refine these models and translate them into clinical practice. By harnessing the power of AI, we can move closer to a future where breast cancer is a preventable disease.
1.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
2.
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer
3.
Germline Profiling May Improve Risk Stratification in t-MNs
4.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
5.
Scientists call into question safety of potential new anticancer treatment
1.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
2.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
3.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
4.
Ferroptosis Signaling in Tumor Progression and Therapeutic Resistance
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Clinical Insights in Hematology
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation